Microbot Medical Reports $72,000 Quarterly Revenue

The medical device maker's third-quarter 2026 revenue fell from the prior quarter while procedure use of its Liberty system rose.

Updated on Nov. 17, 2026 in Healthcare

Microbot Medical Reports $72,000 Quarterly Revenue

Microbot Medical reported third-quarter 2026 revenue of $72,000 for the quarter ended September 30, 2026, down from $241,000 in the second quarter. The company posted a negative gross margin as cost of goods sold, which included an inventory write-down, rose 24% from the prior quarter.

Why it matters

The results show the company still lacks positive gross margins on its endovascular robotic systems, a key challenge for a small medical device maker. Management attributed the revenue decline to the timing of customer reorders and slower summer activity, while procedure utilization of its Liberty system rose 44%.

Revenue fell from $241,000 in Q2 to $72,000 in Q3 2026 while cost of goods sold rose 24%, producing a negative gross margin. Customer accounts increased from 10 to 12 and Liberty procedure utilization rose 44% over the same period.

The players

Microbot Medical

Microbot Medical is a medical device company developing the Liberty endovascular robotic system for minimally invasive vascular procedures.

The details

Management said systems sold in the quarter mostly reflected units built in earlier periods at higher production costs, and that manufacturing cost per unit fell for systems produced in the third quarter. The company cited cost reduction initiatives and a planned second manufacturing line as steps toward a positive gross margin in 2027.

Timeline

  1. Q2 2026: Revenue reached $241,000 for the quarter.

  2. Summer 2026: Customer activity slowed during the summer months.

  3. September 30, 2026: Third-quarter reporting period ended with $72,000 in revenue.

  4. 2027: The company expects to return to a positive gross margin.

Market Landscape

Microbot's Liberty system is a robotic platform for endovascular procedures, and its rising procedure volume against shrinking system revenue reflects the early commercial stage of such devices. Its gross margin pressure parallels the scale-up challenges small medical device makers face before manufacturing costs fall with volume.

For patients, the main near-term effect is limited, since the company reports only 12 customer accounts and early-stage use of its Liberty system. Investors and hospital purchasers should watch whether the planned second manufacturing line and cost reductions restore positive gross margins in 2027.

The takeaway

Revenue volatility in early-stage medical device makers often reflects order timing and manufacturing scale rather than demand alone. Tracking gross margin over the next few quarters will show whether production changes are working.

Further reading

Track more company results in the Healthcare section.

Source note: This article includes information reported by AuntMinnie.